AG-221 (Enasidenib), IHD2 Inhibitor

Overview
Catalog #	bs-60296c-2-mg-solid
Product Name	AG-221 (Enasidenib), IHD2 Inhibitor
Specifications
Storage Buffer	Powder
Storage Condition	Store in dry, dark place at -20C for 1 year.
Target
Product Information	Molecular Weight: 473.38 Formula: C19 H17 F6 N7 O CAS Number: 1446502-11-9 InChi Key: DYLUUSLLRIQKOE-UHFFFAOYSA-N InChi: InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32) Smiles: CC(C)(O)CNC1N=C(N=C(NC2C=CN=C(C=2)C(F)(F)F)N=1)C1C=CC=C(N=1)C(F)(F)F Purity: 98.0 Solubility: DMSO up to 50 mM Appearance: Solid Power. Shelf Life: 1.0 years
Description	Enasidenib, also known as AG-221 and CC-90007, is a potent and selective IDH2 inhibitor with potential anticancer activity (IDH2 = Isocitrate dehydrogenase 2). The mutations of IDH2 present in certain cancer cells result in a new ability of the enzyme to catalyze the NAPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). The production of 2HG is believed to contribute to the formation and progression of cancer . The inhibition of mutant IDH2 and its neoactivity is therefore a potential therapeutic treatment for cancer.